Chembio Inks Commercialization Deal for Dengue, Zika, Chikungunya Tests

May 24, 2018

NEW YORK (360Dx) – Chembio Diagnostics announced today that it has signed an agreement to commercialize its point-of-care tests for Dengue, Zika, and Chikungunya infection in Brazil with Bio-Manguinhos.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Featured White Papers

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Molecular Tests Provide a Better Alternative to Stool Culture for GI Cases

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Mar

19

Featured Webinar

One Test May Not Fit All: Evaluation of Point-of-Care Assays for Influenza Testing

In this webinar, Dr. Matthew Faron, a pathologist from the Medical College of Wisconsin, will share results of a comparison study of three rapid influenza assays.

Mar

20

Featured Webinar

A New Multiplex Syndromic System For Respiratory Diagnosis And Improved Patient Care

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Main menu